Advanced search
Publication Cover
Cell Cycle Volume 12, 2013 - Issue 8
Submit an article Journal homepage
1,181
Views
20
CrossRef citations to date
0
Altmetric
Editorials: Cell Cycle Features

eIF4E3, a new actor in mRNA metabolism and tumor suppression

Laurent Volpon Institute for Research in Immunology and Cancer (IRIC); Department of Pathology and Cell Biology; Université de Montréal; Montreal, QC Canada
,
Michael J. Osborne Institute for Research in Immunology and Cancer (IRIC); Department of Pathology and Cell Biology; Université de Montréal; Montreal, QC Canada
,
Biljana Culjkovic-Kraljacic Institute for Research in Immunology and Cancer (IRIC); Department of Pathology and Cell Biology; Université de Montréal; Montreal, QC Canada
&
Katherine L.B. Borden Institute for Research in Immunology and Cancer (IRIC); Department of Pathology and Cell Biology; Université de Montréal; Montreal, QC CanadaCorrespondence[email protected]
Pages 1159-1160 | Received 25 Mar 2013, Accepted 03 Apr 2013, Published online: 09 Apr 2013

References

  • Graff JR, Zimmer SG. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis 2003; 20:265 - 73; http://dx.doi.org/10.1023/A:1022943419011; PMID: 12741684
  • Topisirovic I, Guzman ML, McConnell MJ, Licht JD, Culjkovic B, Neering SJ, et al. Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol 2003; 23:8992 - 9002; http://dx.doi.org/10.1128/MCB.23.24.8992-9002.2003; PMID: 14645512
  • Culjkovic B, Topisirovic I, Borden KL. Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E. Cell Cycle 2007; 6:65 - 9; http://dx.doi.org/10.4161/cc.6.1.3688; PMID: 17245113
  • von der Haar T, Gross JD, Wagner G, McCarthy JE. The mRNA cap-binding protein eIF4E in post-transcriptional gene expression. Nat Struct Mol Biol 2004; 11:503 - 11; http://dx.doi.org/10.1038/nsmb779; PMID: 15164008
  • Joshi B, Lee K, Maeder DL, Jagus R. Phylogenetic analysis of eIF4E-family members. BMC Evol Biol 2005; 5:48; http://dx.doi.org/10.1186/1471-2148-5-48; PMID: 16191198
  • Osborne MJ, Volpon L, Kornblatt JA, Culjkovic-Kraljacic B, Baguet A, Borden KL. eIF4E3 acts as a tumor suppressor by utilizing an atypical mode of methyl-7-guanosine cap recognition. Proc Natl Acad Sci USA 2013; 110:3877 - 82; http://dx.doi.org/10.1073/pnas.1216862110; PMID: 23431134
  • Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, et al. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 2009; 114:257 - 60; http://dx.doi.org/10.1182/blood-2009-02-205153; PMID: 19433856
  • Michon T, Estevez Y, Walter J, German-Retana S, Le Gall O. The potyviral virus genome-linked protein VPg forms a ternary complex with the eukaryotic initiation factors eIF4E and eIF4G and reduces eIF4E affinity for a mRNA cap analogue. FEBS J 2006; 273:1312 - 22; http://dx.doi.org/10.1111/j.1742-4658.2006.05156.x; PMID: 16519694

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.